241P - NAB-paclitaxel as third-line therapy after failure of gemcitabine and 5-fluorouracil (5-FU) based combinations in advanced gall bladder cancer pati...

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cytotoxic agents
Hepatobiliary Cancers
Presenter Varun Goel
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors V. Goel1, V. Talwar1, N. Patnaik2, S. Raina1, S. Singh1
  • 1Medical Oncology, Rajiv Gandhi Cancer Institute & Research Center, 110085 - New Delhi/IN
  • 2Pathology, UCMS & GTB hospital, 110095 - Delhi/IN

Abstract

Background

In literature, there is no standard third-line chemotherapy, post gemcitabine and fluracil based chemotherapy regimens, in metastatic gall bladder cancer patients. So we have done this study to assess the efficacy and toxicity profile of single agent nab-paclitaxel as a third line chemotherapy in metastatic gall bladder cancer patients.

Methods

In this prospective observational study, metastatic gall bladder cancer patients with performance status ≤2, who progressed on two-lines of therapy, were enrolled from May 2012 to july 2016. Single agent nab-paclitaxel (dose 125mg/m2) was administered on Day 1, 8 and 15 in a cycle of 28 days and i.e. until progression or unacceptable toxicity. Response evaluation was done after 2 cycles of chemotherapy.

Results

A total of 34 patients were enrolled in this study. The median age of patients was 62 years (31–71 years), of which 20 (58.82%) were males and 14 (41.17%) were females. The median number of cycles could be given were 3.5 (0.5 – 9.6). 20 patients (58.82%) could be given more than 3 cycles of chemotherapy and only 3 patients (8.82%) in this study received more than 6 cycles of chemotherapy. Disease control rate was seen in 24 (70.58%) patients, with complete response in none, partial response in 13 (38.23%), stable disease in 11 (32.35%) and progressive disease in 10 (29.41%) patients. The median progression free survival was 3.12 months. The median overall survival was 4.9 months. The main Grade 3/4 side effects seen were hematological in 32.35% (n = 11). 8 patients (23.52%) had Grade 1/2 peripheral neuropathy.

Conclusions

Nab-paclitaxel is an effective and well-tolerated agent as a third-line option in metastatic gall bladder cancer patients. Further studies are required, especially in the Indian subcontinent.

Clinical trial indentification

NA

Legal entity responsible for the study

N/A

Funding

RGCI&RC

Disclosure

All authors have declared no conflicts of interest.